Purpose: To determine whether living related retroperitoneoscopic donor nephrectomy (RDN) is a safe and effective procedure.

Patients And Methods: From September 2001 to May 2004, RDN was performed in 50 consecutive patients at our hospital. All patients were followed longitudinally with office visits. Perioperative and postoperative data for these RDNs, including operative time, blood loss, and complications, were compared with those of open donor nephrectomies (ODNs) performed between January 1999 and December 2001.

Results: The RDN was completed in all cases. The average warm ischemia times were 4.1 minutes (range 1.0-8.5 minutes) and 3.5 minutes (range 2.3-5.5 minutes) in the RDN and ODN groups, respectively (P = NS). The mean operative time for RDN was significantly longer than that for ODN (P < 0.001), but patients in the RDN group had significantly shorter hospital stays (P < 0.05). There was no significant difference between the groups in blood loss during operation or number of doses of analgesics administered after the operation. Perioperative and early postoperative complications occurred in 14 patients (28%) in the RDN group and consisted of subcutaneous emphysema in 9, wound infection in 3, and persistent headache in 2 patients. All kidneys removed retroperitoneoscopically functioned immediately. No recipients required post-transplant continuous hemodialysis.

Conclusions: The RDN is a safe and effective procedure for both donor and recipient. Although the benefits of RDN have been demonstrated, further long-term studies of graft function and patient survival are needed.

Download full-text PDF

Source
http://dx.doi.org/10.1089/end.2005.19.808DOI Listing

Publication Analysis

Top Keywords

rdn
9
open donor
8
donor nephrectomy
8
rdn safe
8
safe effective
8
operative time
8
blood loss
8
minutes range
8
rdn group
8
patients
5

Similar Publications

The tolerance and dynamic regulation of the maternal immune system during pregnancy are pivotal for ensuring fetal health. Immune cell subsets play a complex and crucial role in this process, closely linked to the neonatal health status. Despite recognizing the significance of dysregulation in the quantity and activity of immune cells in neonatal disease occurrence, their specific roles remain elusive, resulting in a dearth of clinically viable interventions for immune-mediated neonatal diseases.

View Article and Find Full Text PDF

Renal denervation for hypertension.

Nat Rev Cardiol

January 2025

Division of Cardiology, Columbia University Irving Medical Center, New York, NY, USA.

Innovative therapies for hypertension are desperately needed given the rising prevalence and falling rates of control of hypertension despite an abundance of available medical therapies. Procedural interventions lower blood pressure without depending on adherence to medications, and endovascular renal denervation (RDN) is the interventional procedure with the best evidence base for the treatment of hypertension. After nearly two decades of study, with major refinements to devices, technique and trial design, two different systems for RDN received approval from the FDA in late 2023 for the treatment of hypertension.

View Article and Find Full Text PDF

Objectives: To develop and validate deep learning (DL)-models that denoise late iodine enhancement (LIE) images and enable accurate extracellular volume (ECV) quantification.

Methods: This study retrospectively included patients with chest discomfort who underwent CT myocardial perfusion + CT angiography + LIE from two hospitals. Two DL models, residual dense network (RDN) and conditional generative adversarial network (cGAN), were developed and validated.

View Article and Find Full Text PDF

The primary aim of this expert narrative review is to unravel the complexities of feeding and eating disorders in the gastroenterology practice setting. We aim to critically assess current assessment screening tools for eating and feeding disorders to gain a comprehensive understanding of how these tools may be misconstrued in the context of gastrointestinal (GI) conditions. Additionally, our objective is to highlight the potential for over-pathologizing and under-pathologizing eating behavior in this patient population.

View Article and Find Full Text PDF

Renal denervation (RDN) is recognized as an adjunct therapy for hypertension management with a favorable and consistent blood pressure-lowering efficacy and safety profile. Alteration in medication burden is another noteworthy outcome of RDN for clinicians and patients. In this review, we summarized current clinical trials and patient perspectives, focusing on the use of antihypertensive medication (AHM) after RDN.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!